About Us
Avalyn is a clinical-stage biotech company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Our goal is to deliver inhaled formulations of effective medicines directly to lung tissue, thus potentially enhancing efficacy and avoiding side effects associated with systemic drug delivery.
Our Pipeline
Our programs are championed by a leadership team with unparalleled expertise in the development of inhaled drugs. Avalyn’s pipeline includes two clinical stage programs, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), and a preclinical stage program, AP03 (a fixed dose combination of inhaled pirfenidone and nintedanib).
Latest News
April 1, 2025
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
Read More